ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
A phase II trial of continuous intravenous infusion of Blincyto given over a 28-day cycle.
Starting day for patients who are MRD-positive before HSCT is between day +60 and day +100
and for patients who become MRD-positive post HSCT it is between day +60 and day +360 post
HSCT.
Patients will be evaluated for response at day +28 (+4 days) (bone marrow morphology and MRD
analysis - defined by PCR/FLOW-techniques) after start of Blincyto-treatment at the end of
first Blincyto infusion and at regular post-TX-checks (according to FORUM: days +28, +60,
+100, +180 and +360 after HSCT).
The dose of Blincyto used in this trial will be 15 mcg/m2/day for 28 days